Glow Lifetech Corp. (GLWLF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 87.63 Thousand USD | 4.06% |
| 2022 | 84.21 Thousand USD | 112.86% |
| 2021 | -654.83 Thousand USD | -13230.41% |
| 2020 | 4987.13 USD | 153.22% |
| 2019 | -9370.00 USD | -235.01% |
| 2018 | -2796.90 USD | -105.29% |
| 2017 | 52.85 Thousand USD | 322311.65% |
| 2016 | -16.41 USD | 96.14% |
| 2015 | -424.74 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 286.72 Thousand USD | 234.4% |
| 2024 Q2 | -5139.00 USD | -101.81% |
| 2023 Q1 | 495.78 Thousand USD | 10.41% |
| 2023 Q4 | 87.63 Thousand USD | -88.46% |
| 2023 Q3 | 759.26 Thousand USD | 5.93% |
| 2023 Q2 | 716.77 Thousand USD | 44.57% |
| 2023 FY | 87.63 Thousand USD | 4.06% |
| 2022 Q2 | 4540.25 CAD | 102.3% |
| 2022 Q1 | -197.4 Thousand CAD | 69.85% |
| 2022 Q4 | 449.04 Thousand USD | 127.83% |
| 2022 FY | -24.48 Thousand USD | 112.86% |
| 2022 Q3 | 197.09 Thousand USD | 4241.08% |
| 2021 Q1 | -2.6 Million CAD | -3344.2% |
| 2021 FY | -654.83 Thousand USD | -13230.41% |
| 2021 Q4 | -654.83 Thousand CAD | 40.63% |
| 2021 Q3 | -1.1 Million CAD | 35.13% |
| 2021 Q2 | -1.7 Million CAD | 34.66% |
| 2020 FY | 4987.13 USD | 153.22% |
| 2020 Q4 | -75.54 Thousand CAD | -1361.04% |
| 2020 Q3 | 5991.00 CAD | 56.26% |
| 2020 Q2 | 3834.00 CAD | -2.44% |
| 2020 Q1 | 3930.00 CAD | 127.97% |
| 2019 FY | -9370.00 USD | -235.01% |
| 2019 Q4 | -14.05 Thousand CAD | 0.0% |
| 2018 FY | -2796.90 USD | -105.29% |
| 2017 FY | 52.85 Thousand USD | 322311.65% |
| 2016 FY | -16.41 USD | 96.14% |
| 2015 FY | -424.74 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Qrons Inc. | 351.42 Thousand USD | 75.063% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 101.39% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 135.107% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -341.103% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.568% |
| BioStem Technologies, Inc. | 4.47 Million USD | 98.04% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 98.449% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.795% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.798% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 86.203% |
| Skye Bioscience, Inc. | -5.72 Million USD | 101.532% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 529.41% |
| Rebus Holdings, Inc. | 305 Thousand USD | 71.268% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 6789.618% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 85.919% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.444% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 97.872% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 78.192% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.242% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 96.092% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 90.548% |
| Mesoblast Limited | 55.85 Million USD | 99.843% |
| Marizyme, Inc. | 18.56 Million USD | 99.528% |
| Genus plc | 190.6 Million USD | 99.954% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 96.08% |
| Pharming Group N.V. | 109.8 Million USD | 99.92% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 89.813% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 92.781% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 87.113% |
| ContraFect Corporation | -6.02 Million USD | 101.454% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 34.912% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 92.415% |
| IMV Inc. | 7.67 Million USD | 98.858% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 98.407% |
| MultiCell Technologies, Inc. | 90.04 USD | -97227.854% |
| ONE Bio Corp. | 9.04 Million USD | 99.031% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 111.94% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 99.323% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 93.594% |
| Q BioMed Inc. | 4.06 Million USD | 97.842% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.713% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 91.304% |
| Biomind Labs Inc. | 711.4 Thousand USD | 87.682% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.855% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 95.617% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 99.316% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 75.638% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 37.317% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 96.02% |
| GB Sciences, Inc. | 1.74 Million USD | 94.985% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 147.682% |
| HST Global, Inc. | 96.79 Thousand USD | 9.462% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 57.504% |
| Halberd Corporation | 144.72 Thousand USD | 39.446% |
| Enzolytics Inc. | 981.65 Thousand USD | 91.073% |
| Agentix Corp. | 37.63 Thousand USD | -132.877% |
| Resverlogix Corp. | 6.45 Million USD | 98.642% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 113.02% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.004% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.186% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 98.761% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 96.765% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 100.991% |
| AVAX Technologies, Inc. | -5.9 Million USD | 101.485% |
| Zenith Capital Corp. | 10.06 Thousand USD | -770.767% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.008% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 56.277% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 96.327% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 46.73% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 578.404% |
| Kadimastem Ltd | -253.1 Thousand USD | 134.624% |
| Helix BioMedix, Inc. | -2.57 Million USD | 103.41% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 56.456% |
| LadRx Corporation | -2.03 Million USD | 104.303% |
| Cell Source, Inc. | 9.23 Million USD | 99.051% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 86.203% |
| NovAccess Global Inc. | 2.17 Million USD | 95.977% |
| Affymax, Inc. | -5.59 Million USD | 101.566% |
| Itoco Inc. | 228.3 Thousand USD | 61.615% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 35.558% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 98.232% |
| Mobile Lads Corp. | 484.23 Thousand USD | 81.902% |
| CytoDyn Inc. | 20.26 Million USD | 99.567% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 13644.668% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 1045.52% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 98.863% |
| SYBLEU INC | 473.71 Thousand USD | 81.501% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 98.034% |
| International Stem Cell Corporation | 2.59 Million USD | 96.616% |
| Bioxytran, Inc. | 1.89 Million USD | 95.385% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -40.41% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 95.982% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 97.448% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 98.975% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 88.657% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 107.011% |
| Neutra Corp. | 52.18 Thousand USD | -67.923% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 103.521% |
| PureTech Health plc | -167.19 Million USD | 100.052% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 135.782% |
| IXICO plc | -4.44 Million USD | 101.972% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 99.337% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.84% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Cellectis S.A. | -43.81 Million USD | 100.2% |